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Background: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR)
and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%–45% of
gastric cancers, making them potential targets.
Patients and methods: The primary objective of this study was to assess response rate. Secondary objectives
included overall survival (OS), toxicity, and the relationship of EGFR, ErbB2, and markers of angiogenesis with clinical
outcome. Lapatinib was administered to chemonaive metastatic gastric cancer patients at a dose of 1500 mg orally
daily for 28 days.
Results: The study enrolled 47 patients from February 2005 until May 2006. Four patients (9%) had a conﬁrmed
partial response (PR), 1 (2%) had an unconﬁrmed PR, and 10 (23%) had stable disease. Median (95% conﬁdence
interval) time to treatment failure was 1.9 (1.6–3.1) months and OS was 4.8 (3.2–7.4) months. Signiﬁcant adverse
events: one grade 4 cardiac ischemia/infarction, one grade 4 fatigue, and one grade 4 emesis. One treatment-related
death was due to central nervous system ischemia. An exploratory analysis of markers revealed gene expression of
HER2, interleukin (IL)-8 and genomic polymorphisms IL-8, and vascular endothelial growth factor correlated with OS.
Conclusions: Lapatinib is well tolerated, with modest single-agent activity in advanced/metastatic gastric cancer
patients. Potential molecular correlatives were identiﬁed which warrant further validation.
Key words: EGFR, gastric cancer, HER2, lapatinib
introduction
In 2010, there were an estimated 21 000 new cases of gastric
cancer in the United States with 10 570 deaths and an overall
5-year survival rate of 22% [1]. Only 20% of cases are
diagnosed at an early, potentially curable, stage.
Many chemotherapeutic drugs have single-agent activity in
advanced disease, including ﬂuoropyrimidines, platinums,
irinotecan, taxanes, and adriamycin. Combination regimens
have been shown to be more effective, with response rates
ranging from 30% to 50%. However, there can be signiﬁcant
toxicity associated with these combinations and historically,
median survival has been 6–9 months. There are more recent
phase II and III studies that have reported longer survival, some
>1 year [2]. Nevertheless, there remain limitations of
traditional therapies and promising preliminary data with novel
targeted therapeutics, newer agents are being investigated.
One potential therapeutic target is the epidermal growth
factor receptor (EGFR). Both the EGFR and human epidermal
growth factor receptor 2 (HER2) genes are ampliﬁed and
overexpressed in a variety of solid human cancers and are
associated with a poor prognosis in patients with gastric cancer.
Preclinical studies have shown a signiﬁcant number of gastric
cancer cell lines express EGFR, which grow in response to EGF
and transforming growth factor-a and show a greater degree of
gastric wall invasion and lymph node metastasis, representing
greater malignant potential [3–5]. Additionally, EGFR
expression is signiﬁcantly higher in gastric carcinoma than in
adjacent normal gastric mucosa, with greater EGFR levels
found in more advanced tumors [6]. Yasui et al. [7] evaluated
gastric carcinoma samples for EGFR by 125-labeled EGF
binding, with EGFR expression immunoreactivity detected in
33 (34%) of the 96 advanced gastric cancers. Similarly,
evaluation by He et al. [8] of 104 specimens of gastric cancer
revealed that 42% demonstrated expression of EGFR.
Simultaneous EGF and EGFR expression was noted in 15% of
gastric cancers, suggesting that these tumors may grow in an
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were found to be positive for c-ErB2 [9].
HER2 has also been associated with poor prognosis, and
expression of HER2 assessed in many trials and tissue series in
gastric cancer specimens have shown conﬂicting results. This
may be due to the differing methodology used in measuring
HER2 status [6]. In fact, evaluations of both EGFR and HER2
have revealed varying expression, which may relate to the
methods used to evaluate these markers [10–12]. Most recently,
HER2 expression was noted to be 22% in the ToGA
trial, carried out by both FISH and immunohistochemistry
(IHC) [13].
In the laboratory, the combination of anti-EGFR and anti-
ErB2 mAbs results in additive antiproliferative effects,
suggesting a potential beneﬁt of this combined therapy in the
treatment of cancers stimulated by EGFR and HER2 signals.
Lapatinib was approved by the Food and Drug
Administration in March 2007 for use in patients only in
combination with capecitabine for HER2-positive breast cancer
patients, who have completely responded to previous
chemotherapy with anthracycline, taxanes, and trastuzumab
[14]. Preclinical data have shown that lapatinib, an ErbB1
(EGFR) and ErB2 (HER2) inhibitor, may down-regulate
thymidylate synthase in vitro.
The antitumor effect of lapatinib in gastric cancer cell lines
has been reported to have the greatest effects in HER2-
ampliﬁed cells [15]. Lapatinib inhibited phosphorylation of
HER2, EGFR, and downstream signaling proteins resulting in
G1 arrest and induction of apoptosis [16].
Lapatinib, a dual tyrosine kinase inhibitor of both EGFR and
HER2/erbB2, is thought to react with the ATP binding site of
protein kinases, competing with the ATP substrate inhibiting
EGFR/HER2 autophosphorylation through this competition.
Treatment with lapatinib in tumor xenografts that
overexpressed both EGFR and HER2 resulted in reduced levels
of phosphorylated tyrosine, which correlated with inhibition of
tumor growth [17]. Apoptosis and arrest of tumor cell growth
have been demonstrated with this agent, even in the presence of
saturating concentrations of EGF [18]. Lapatinib has been
shown to inhibit Erk1/2 and Akt phosphorylation (pErk and
pAkt) in both EGFR and ErB2-expressing cell lines (BT474 and
HN5). The ability of lapatinib to inhibit pAkt was associated
with a 23-fold increase in the percentage of cells undergoing
apoptosis compared with control cells. These results suggest
that lapatinib treatment of EGFR/ErB2-expressing tumors
could lead to inhibition of downstream signaling events [18].
Given evidence of expression of EGFR and potentially,
HER2/ErB2 in patients with gastric cancer, and preclinical
evidence that blockade of these receptors may lead to inhibition
of cell growth and apoptosis, a phase II study using lapatinib as
a single agent for patients with advanced or metastatic
gastric cancer was conducted through the Southwest
Oncology Group (SWOG) (ClinicalTrials.govIdentiﬁer: NCT
00103324].
patients and methods
Study eligibility included the following: cytologically or pathologically
veriﬁed diagnosis of advanced or metastatic adenocarcinoma gastric cancer
not surgically curable; measurable disease by RECIST criteria; 2-week
period between any surgery and study entry; completion of prior
chemotherapy, hormonal therapy, immunotherapy, radiation therapy (to
<25% of bone marrow), or chemoradiotherapy as neoadjuvant or adjuvant
treatment at least 6 months before documented recurrence or advanced/
metastatic disease; Zubrod’s performance status from 0 to 1; ability to
swallow and/or receive enteral medications via gastrostomy feeding tube
(including ability to absorb medication); adequate bone marrow reserve as
evidenced by absolute granulocyte count ‡1500/ll and platelets ‡100 000/
ll; adequate hepatic function as evidenced by serum bilirubin £
institutional upper limit of normal (IULN), serum transaminases [serum
glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic
transaminase (SGPT)] £2.5 · (IULN) [if liver metastasis were present,
SGOT or SGPT had to be £5 · (IULN)]; measured or calculated creatinine
clearance of >60 ml/min (utilizing G–K equation); cardiac ejection fraction
within the institutional range as measured by echocardiogram or Multi
Gated Acquisition (MUGA) scan. Patients must not have received previous
treatment of metastatic disease or received any prior therapy with EGFR
targeting therapies. Human immunodeﬁciency virus-positive patients were
excluded because of possible pharmacokinetic interactions with
antiretroviral therapy. HER2 ampliﬁcation was not an entry criterion for
this study. All patients must have signed the informed consent in
accordance with institutional and federal guidelines.
study design
This was a phase II, open-label, multicenter trial administered and
monitored by SWOG. The primary objective of this study was to assess the
response rate of lapatinib in patients with advanced/metastatic gastric
cancer. Secondary objectives included (i) assessment of overall survival
(OS) in these patients; (ii) quantitative and qualitative toxic effects of this
regimen; (iii) preliminary assessment of the relationship of protein
expression and gene expression of EGFR, HER2, markers of angiogenesis
[cyclooxygenase (COX)-2, vascular endothelial growth factor (VEGF),
interleukin (IL)-8], and cell cycle (Cyclin D1) with clinical outcome in this
study population.
Patients received lapatinib 1500 mg orally days 1 through 28. The drug
was administered continuously, with one cycle deﬁned as 28 days. Tablets
were available in a strength of 250 mg, and a total of six were taken daily.
Concomitant medications that were considered gastric pH modiﬁers were
not permitted. The use of antacids was permitted, but these were
administered within 1 hour before or after dosing. Dose adjustments were
made for grade 3 toxicity or greater. The ﬁrst dose reduction was from 1500
to 1000 mg/day, the second dose reduction 750 mg/day, and if a third dose
reduction was required, patients were taken off study. Patients continued
on protocol treatment until disease progression, symptomatic
deterioration, unacceptable toxicity, treatment delay for any reason >4
weeks, or withdrawal of consent.
treatment assessments
Baseline assessments included medical history and physical examination,
performance status, complete blood count with differential and platelet
count, bilirubin, SGOT and SGPT, creatinine clearance, diagnostic tumor
imaging, electrocardiogram and submission of parafﬁn-embedded tumor
specimen, and a blood sample. An echocardiogram or MUGA was also
carried out and required every 8 weeks. During the study, history, physical
exam, performance status, blood counts, SGOT, SGPT, and creatinine
clearance were evaluated every 4 weeks. Toxicity assessment, based on the
National Cancer Institute Common Toxicity Criteria, version 2, was carried
out every 4 weeks. Tumor response assessments were done after every two
cycles. Disease assessment was mandated every 9 weeks while patients were
on protocol treatment and every 3 months after they were off protocol
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RECIST. A second sample of blood for molecular correlates was collected 4
weeks after registration.
molecular correlates
genotyping. Peripheral blood or parafﬁn-embedded tissue samples were
available from 41 eligible patients. Genomic DNA was extracted from white
blood cells or parafﬁnized tissue using the QiAmp kit (Qiagen, Valencia,
CA). Genomic DNA was obtained in 37 patients from peripheral blood and
in four patients from parafﬁn-embedded tissue. These 41 genomic DNA
samples were used to analyze all polymorphisms.
Single nucleotide polymorphisms were tested using PCR–RFLP
technique as previously described. Brieﬂy, forward and reverse primers were
used for PCR ampliﬁcation, PCR products were digested by restriction
enzymes (New England Biolab, Massachussetts, MA), and alleles were
separated on 4% NuSieve ethidium bromide-stained agarose gel. In case no
restriction enzyme could be found, samples were analyzed by
direct sequencing. For the EGFR (CA)n dinucleotide repeat, the 5# end
[33P-]cATP labeled PCR protocol was used.
gene expression levels. Thirty-seven parafﬁn-embedded tissue samples were
available for gene expression assay. Laser captured microdissection,
messenger RNA (mRNA) isolation, complementary DNA (cDNA)
synthesis, and real-time PCR quantiﬁcation of mRNA expression were
carried out.
statistical design
The primary goal of this study was to evaluate the conﬁrmed response
probability (complete and partial) in patients with advanced/metastatic
gastric cancer treated with lapatinib. Time to treatment failure (TTF) and
OS were secondary end points. It is assumed that this therapy would be of
no further interest if the true response probability was 5% or less and of
interest if the true response probability was 20% or more. The study
employed the two-stage design of Green and Dahlberg [19].
If, after the ﬁrst 20 patients, at least one conﬁrmed response was
observed, an additional 20 patients were to be accrued. Five or more
responses in the total of 40 were considered evidence that this regimen is of
interest in the treatment of advanced/metastatic gastric cancer. This design
had a power of 0.92 when the true response is 20%, at a signiﬁcance level of
0.05. Forty patients were sufﬁcient to estimate the probability of a particular
toxicity to within 616%. Any toxicity occurring with at least a 5%
probability was likely (87%) to be seen at least once.
Additionally, the relationship of protein expression and gene expression
of EGFR and HER2 and markers of angiogenesis and downstream
regulatory markers were to be compared in a very preliminary fashion with
clinical outcomes. The associations between gene polymorphisms and
response were evaluated by Chi-squared test. The associations between gene
polymorphisms and OS were examined using Kaplan–Meier plots and the
log-rank test.
results
patient characteristics
From February 2005 to May 2006, 47 patients were accrued.
Two patients did not receive any treatment and are not
analyzable for any end point (one of whom was also ineligible
due to no measurable disease). One other patient whose disease
recurred too soon after adjuvant therapy was ineligible. Baseline
characteristics for the 44 eligible and assessable patients are
presented in Table 1.
treatment delivery
The median duration of protocol treatment was 1.9 months
(range 0.3–12.5 months). Reasons for treatment
discontinuation include progressive disease (84%), death (7%),
toxicity (7%), and patient refusal (2%). Of the 44 eligible
patients, 28 (64%) had their lapatinib dose reduced.
treatment efﬁcacy
There were four partial responses (PRs) in 44 assessable
patients, with no complete responses observed, for an
overall conﬁrmed response rate of 9% [95% conﬁdence interval
(CI) 3–22%]. There was also one unconﬁrmed PR for an
overall response rate of 11%. There were 10 (23%) patients
with stable disease. The remainder was not assessable for
response (N = 2) or had early progression (N = 27).
Patients who could not be assessed for response were treated as
non-responders and included in the denominator. With all
patients now off protocol treatment, the median TTF was 1.9
months (95% CI 1.6–3.1). Forty-three (98%) patients have
died, with a median OS of 4.8 months (95% CI 3.2–7.4)
(Figure 1).
toxicity
There were 15 (34%) grade 3 and 3 (7%) grade 4 adverse
events. The most common grade 3 events were fatigue (8),
anorexia (7), and diarrhea (4). There was one treatment-related
death due to CNS ischemia. One patient each experienced
grade 4 fatigue, cardiac ischemia/infarction, and vomiting. Of
note, there were no left ventricular ejection fraction
abnormalities recorded at baseline or during the course of the
study.
Table 1. Patient and tumor characteristics (N = 44)
Age (years)
Median 68.7
Range 38.9–90
Sex (%)
Male 29 (66)
Female 15 (34)
Race (%)
White 35 (80)
Black 4 (9)
Asian 4 (9)
Unknown 1 (2)
Zubrod performance status (%)
0 15 (34)
1 29 (66)
Number of metastatic sites (%)
0 1 (2)
1 15 (34)
2 15 (34)
3+ 13 (30)
Prior therapy (%)
Surgery 12 (27)
Chemotherapy 3 (7)
Radiation 8 (18)
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Genomic DNA from 41 patients was available for evaluation of
eight polymorphisms in the seven genes of interest. Genotyping
assays for the polymorphisms were successful as follows: 41
patients for COX-2, Cyclin D1, EGF, EGFR 497, HER2, and IL-8;
37 patients for EGFR (CA)n repeats; and 40 patients for VEGF.
Table 2 describes patient outcomes within each polymorphism-
based subgroup. There were four partial responders in the group
of patients with IL-8 AA genotype compared with none in the
group with AT or TT genotype. Patients with VEGF CC
genotype had 3% (1/30) response rate, while patients with
CT genotype had 22% (2/9) response rate and those with TT
genotype had 100% (1/1) response rate. Patients with the IL-8
A/A genotype had median (95% CI) OS of 9.6 (3.0–11.2) months,
longer than either the A/T [4.9 (3.2–7.4)] or the T/T [3.0 (2.5–
4.8)] genotypes, although this result was not statistically
signiﬁcant (P = 0.20). None of the remaining polymorphisms
tested were associated with either response or survival (Table 2).
Tumor cDNA from 36 microdissected tumor tissue
specimens were available for the measurement of gene
expression levels of six genes of interest. The median values
used for the gene expression analyses were EGFR, 2.715; HER2,
0.065; IL-8, 16.59; VEGF, 5.88; COX-2, 1.94; and CYCLIN D1,
8.77. The gene expression assay was successful as follows: 33
patients for HER2, 34 patients for COX-2 and VEGF, 35
patients for EGFR and IL-8, 36 patients for CyclinD1, and 36
patients for EGFR gene expression levels. Table 3 summarizes
tumor response and OS by intratumoral gene expression levels.
Higher HER2 and lower IL-8 gene expression levels were
signiﬁcantly (P < 0.05) associated with improved OS, although
these P values have not been adjusted for multiple comparisons.
For none of the remaining genes were expression levels
signiﬁcantly associated with OS.
discussion
The current standard treatment of advanced gastric cancer
includes two or three drug regimens, which can produce
signiﬁcant toxicity with limited efﬁcacy. No targeted single-
agent biologic therapy to date has demonstrated signiﬁcant
activity. In this study, single agent lapatinib demonstrated a
conﬁrmed response rate of 9% (overall response rate of 11%)
and a median overall survival of 4.8 months.
Clinically, single-agent activity with EGFR inhibitors have
been evaluated in a very limited fashion in patients with gastric
and gastroesophageal junction adenocarcinoma. Dragovich
et al. [20] reported a phase II study using erlotinib in this
population and did not ﬁnd any signiﬁcant activity in gastric
cancer but did have a 9% conﬁrmed response rate in
gastroesophageal junction tumors. Other trials have shown
limited efﬁcacy of these agents in esophageal cancer and no
signiﬁcant efﬁcacy in patients with gastric cancer. Combination
therapy with cytotoxics plus EGFR inhibition, i.e. cetuximab
has demonstrated promising results in esophageal and
Table 2. Response and overall survival by polymorphisms
Marker N RECIST
response (%)
Overall
survival
Yes No Median
(95% CI),
months
P
a
COX-2
G/C 12 0 (0) 12 (100) 5.9 (3.0–9.9) 0.57
G/G 29 4 (14) 25 (86) 4.7 (3.0–8.7)
Cyclin D1
A/A 13 1 (8) 12 (92) 3.8 (3.0–9.9) 0.46
A/G 18 1 (6) 17 (94) 4.9 (3.3–7.4)
G/G 10 2 (20) 8 (80) 4.5 (1.1–13.5)
EGF
A/A 10 0 (0) 10 (100) 4.9 (3.3–7.4) 0.92
A/G 22 3 (14) 19 (86) 3.4 (2.5–9.9)
G/G 9 1 (11) 8 (89) 7.6 (3.0–9.9)
EGFR
A/A 21 2 (10) 19 (90) 3.3 (2.5–7.6) 0.38
A/G 13 2 (15) 11 (85) 6.1 (4.7–10.4)
G/G 7 0 (0) 7 (100) 7.4 (1.3–13.5)
EGFR (CA)n repeats
At least 1 allele ‡20 17 0 (0) 17 (100) 4.7 (2.2–9.9) 0.94
Both alleles <20 20 3 (15) 17 (85) 4.9 (3.3–7.4)
HER2
Ile/Ile 28 3 (11) 25 (89) 4.8 (3.0–9.2) 0.86
Ile/Val 10 1 (10) 9 (90) 4.7 (2.2–9.9)
Val/Val 3 0 (0) 3 (100) 5.0 (NA)
IL-8
A/A 14 4 (29) 10 (71) 9.6 (3.0–11.2) 0.20
A/T 18 0 (0) 18 (100) 4.9 (3.2–7.4)
T/T 9 0 (0) 9 (100) 3.0 (2.5–4.8)
TF A-603G
A/A 14 2 (14) 12 (86) 4.2 (3.0–9.9) 0.37
A/G 18 2 (11) 16 (89) 5.3 (3.0–10.5)
G/G 9 0 (0) 9 (100) 6.1 (2.1–9.2)
VEGF
C/C 30 1 (3) 29 (97) 4.9 (3.3–7.6) 0.79
C/T 9 2 (22) 7 (78) 3.0 (3.0–10.4)
T/T 1 1 (100) 0 (0) NA
aP values from Cox regression test for heterogeneity across subgroups; not
adjusted for multiple comparisons.
CI, conﬁdence interval; COX-2, cyclooxygenase-2; EGFR, epidermal growth
factor receptor; HER2, human epidermal growth factor receptor 2; IL-8,
interleukin 8; N/A, not applicable; VEGF, vascular endothelial growth
factor.
Figure 1. Overall survival Kaplan–Meier curve in patients with advanced
or metastatic gastric cancer treated with lapatinib as first-line therapy.
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encouraging responses have been reported in phase II studies
with cetuximab in combination with 5-FU/lecovorin (LV)/
irinotecan with a time to progression of 8 months and
combinations with 5-FU/LV and oxaliplatin with a reported
time to progression of 7.6 months [22, 23].
HER2 ampliﬁcation has been reported as an independent
prognostic and potentially, predictive factor in gastric cancer.
The utility of trastuzumab, the monoclonal antibody targeting
HER2, has been limited in its evaluation and efﬁcacy until
recently. Van Cutsem et al. [13] presented data from the ToGA
trial, a randomized phase III multicenter study, where more
than 3800 patients with adenocarcinoma of the stomach or
gastroesophageal junction were screened and 810 were positive
for HER2 (22.1%). These patients were randomized to receive
ﬂuoropyrimidine with cisplatin and trastuzumab versus
chemotherapy alone [13]. Patients were either HER2 positive
by IHC3+ and/or FISH+. The OS for patients receiving
chemotherapy with trastuzumab was 13.8 versus 11.1 months
for patients receiving ﬂuoropyrimine and cisplatin alone,
hazard ratio 0.74 (0.60–0.91), P = 0.0046. The secondary end
point of progression-free survival and response rate were also
statistically superior in the patients receiving ﬂuropyrimidine,
platinum, and trastuzumab. The combination was well
tolerated. This is the ﬁrst time a biological agent resulted in a
survival beneﬁt in advanced gastric cancer.
To explore potential molecular markers, we evaluated gene
expression levels of six genes of interest in 36 patients and eight
germ-line polymorphisms in seven genes of interest in 41
treated patients. These genes included those involved in EGFR
pathway (EGFR, EGF and HER2), angiogenesis pathway (COX-
2, VEGF and IL-8), and cell cycle pathway (CyclinD1). We
found that patients with higher HER2 or lower IL-8 gene
expression levels had increased OS. These data are consistent
with previously reported in vitro data published by Rusnak
et al. [24], wherein lapatinib sensitivity is increased in human
cell lines with high levels of HER2 expression [15, 16]. This has
also been shown in previous reports for HER2 therapy with
treatment with trastuzumab in breast cancer [25, 26]. HER2
evaluation by FISH was not carried out due to limitations with
tissue samples in this study. HER2 gene expression has been
correlated with ampliﬁcation in prior reports [27].
Polymorphisms in IL-8 and VEGF, both involved in
angiogenesis, showed some correlation with response and were
signiﬁcantly associated with OS. These data suggest that both
EGFR and genes in the angiogenesis pathways may play a role
in determining the efﬁcacy of lapatinib. However, due to the
small number of the patients involved in our biomarker study,
our preliminary results should be interpreted cautiously, with
these ﬁndings validated in a larger prospective clinical trial.
Evaluation of EGFR or HER2 status was not required for
participation in this study. The patients were thereby not
selected based on the tumor characteristics, which may have
affected the potential efﬁcacy of the drug. This may be
particularly signiﬁcant given that the lapatinib has
demonstrated antitumor activity in HER2-ampliﬁed gastric
cancer cell lines and HER2 ampliﬁcation was found to be an
important predictive factor for the growth inhibitory activity of
lapatinib in gastric cancer [15, 16]. In terms of EGFR
expression, there has not been association between EGFR
protein expression and sensitivity to any of the HER-targeted
agents [15]. Furthermore, preclinical data have shown lapatinib
combined with 5-FU, cisplatin, oxaliplatin, or paclitaxel
demonstrate an additive or synergistic effect [16, 28].
In this study, single-agent lapatinib demonstrated limited
activity, although similar to some reports of treatment with
single-agent chemotherapy in advanced/metastatic gastric
cancer [2, 29]. Prior evaluation of single-agent ‘targeted
treatment’ of EGFR or HER2 blockade as single agents has not
demonstrated any signiﬁcant responses. Dual inhibition of
HER2 and EGFR did result in modest activity and provides
support for combination treatment and screening for HER2
in advanced gastric cancer.
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